NCT04664179View on ClinicalTrials.gov

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

April 1, 2026

Study Completion Date

March 30, 2039

Conditions
EBV-Related Hodgkin LymphomaEBV-Related Lymphoproliferative DisorderEBV Related Non-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

Dose Level 1A: 2 x 10^7 cells/m2

2 x 10\^7 cells/m2

BIOLOGICAL

Dose Level 2A: 6 x 10^7 cells/m2

6 x 10\^7 cells/m2

BIOLOGICAL

Dose Level 2B: 6 x 10^7 cells/m2

6 x 10\^7 cells/m2

BIOLOGICAL

Dose Level 3B: 2 x 10^8 cells/m2

2 x 10\^8 cells/m2

BIOLOGICAL

Dose Level 3A: 2 x 10^8 cells/m2

2 x 10\^8 cells/m2

Trial Locations (2)

77030

RECRUITING

Houston Methodist Hospital, Houston

NOT_YET_RECRUITING

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Baylor College of Medicine

OTHER